Literature DB >> 10551775

p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells.

M K Samuelsson1, A Pazirandeh, B Davani, S Okret.   

Abstract

Glucocorticoids exert antiproliferative effects on a number of cell types, including the HeLa cervical carcinoma cell line. However, the mechanism responsible for the antiproliferative effect is poorly understood. In this report we have investigated the role of the recently identified cyclin-dependent kinase inhibitor (CDI) p57Kip2 in the antiproliferative effect conferred by glucocorticoids. When HeLa cells were treated with the synthetic glucocorticoid dexamethasone (DEX), the doubling time of exponentially growing cells increased 2-fold. Within 11 h of DEX treatment, this was accompanied by an accumulation of cells in the G1 phase of the cell cycle with a corresponding decreased proportion of cells in the S phase and decreased CDK2 activity. DEX treatment of the HeLa cells dramatically induced the protein and mRNA expression of the CDI p57Kip2. This induction was seen within 4 h of DEX treatment, preceding a major DEX-induced accumulation of cells in the G1 phase. DEX-induced mRNA expression of p57Kip2 did not require de novo protein synthesis, and the transcription of the p57Kip2 gene was increased as determined by a run-on transcription assay. Furthermore, DEX induction of p57Kip2 was not a consequence of the cell cycle arrest, since other growth inhibition signals did not result in strong p57Kip2 induction. Overexpression of p57Kip2 using HeLa cells stably transfected with a tetracycline-inducible vector showed that p57Kip2 is sufficient to reconstitute an antiproliferative effect similar to that seen in DEX-treated cells. Selective p57Kip2 expression by the tetracycline analog doxycycline to levels comparable to those observed on DEX induction resulted in a 1.7-fold increase in the doubling time and a shift of HeLa cells to the G1 phase as well as a decrease in CDK2 activity. Taken together, these results suggest that glucocorticoid treatment directly induces transcription of the p57Kip2 gene and that the p57Kip2 protein is involved in the glucocorticoid-induced antiproliferative effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551775     DOI: 10.1210/mend.13.11.0379

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  22 in total

1.  An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.

Authors:  T Joshi; M Johnson; R Newton; M Giembycz
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

Review 2.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

3.  Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors.

Authors:  Yen-Shen Lu; Huang-Chun Lien; Pei-Yen Yeh; Kun-Huei Yeh; Min-Liang Kuo; Sung-Hsin Kuo; Ann-Lii Cheng
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

4.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

5.  CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Authors:  Yihong Ma; Lu Chen; Gabriela M Wright; Smitha R Pillai; Srikumar P Chellappan; W Douglas Cress
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

6.  Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.

Authors:  Devin T Worster; Tobias Schmelzle; Nicole L Solimini; Eric S Lightcap; Bjorn Millard; Gordon B Mills; Joan S Brugge; John G Albeck
Journal:  Sci Signal       Date:  2012-03-06       Impact factor: 8.192

Review 7.  Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Authors:  Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2016-11-09       Impact factor: 8.739

8.  Sustained low-dose dexamethasone delivery via a PLGA microsphere-embedded agarose implant for enhanced osteochondral repair.

Authors:  Robert M Stefani; Andy J Lee; Andrea R Tan; Saiti S Halder; Yizhong Hu; X Edward Guo; Aaron M Stoker; Gerard A Ateshian; Kacey G Marra; James L Cook; Clark T Hung
Journal:  Acta Biomater       Date:  2019-12-02       Impact factor: 8.947

9.  Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation.

Authors:  Takumi Kamura; Taichi Hara; Shuhei Kotoshiba; Masayoshi Yada; Noriko Ishida; Hiroyuki Imaki; Shigetsugu Hatakeyama; Keiko Nakayama; Keiichi I Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

10.  Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer.

Authors:  Young-Kook Kim; Jieun Yu; Tae Su Han; Seong-Yeon Park; Bumjin Namkoong; Dong Hyuk Kim; Keun Hur; Moon-Won Yoo; Hyuk-Joon Lee; Han-Kwang Yang; V Narry Kim
Journal:  Nucleic Acids Res       Date:  2009-01-19       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.